HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
Status:
Withdrawn
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The combination of optimal cytoreductive operation (according to Desktop II criteria), HIPEC
with Carboplatin 800 mg/m² KOF (Körperoberfläche) and following platinum-based systemic
chemotherapy should be executed In patients with platinum-sensitive recurrence of ovarian
carcinoma. Condition for HIPEC is attainment of optimal cytoreduction (R0) and experts
judgement of a complication-free prolongation of narcosis after finishing the surgery. HIPEC
will be administered additionally to standard therapy. If HIPEC was executed the number of
systemic given platinum-based chemotherapy decreases for one cycle.
This regime should be investigated in terms of safety of performance, quality of life for the
patients and consequences for the following systemic chemotherapy.